No Data
No Data
Cocrystal Pharma Reports Positive Phase 1 Study Results
Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug CDI-988 For Prophylaxis And Treatment Of Norovirus, Coronaviruses And Other Viral Infections; Data Show Favorable Safety And Tolerability With Dosing Up To 800 Mg For 10...
Express News | Cocrystal Pharma Inc - Plans Human Challenge Study in 2025 for Norovirus
Express News | Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug Cdi-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
Top Midday Decliners
Cocrystal Pharma Shares Fall After Flu-Treatment Study Is Extended